- Home
- ARVN vs CGEM Comparison
ARVN vs CGEM Comparison
Compare ARVN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- CGEM
- Stock Information
- Founded
- ARVN 2015
- CGEM 2016
- Country
- ARVN United States
- CGEM United States
- Employees
- ARVN N/A
- CGEM N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- CGEM Health Care
- Exchange
- ARVN Nasdaq
- CGEM Nasdaq
- Market Cap
- ARVN 456.2M
- CGEM 482.7M
- IPO Year
- ARVN 2018
- CGEM 2021
- Fundamental
- Price
- ARVN $7.90
- CGEM $7.72
- Analyst Decision
- ARVN Buy
- CGEM Strong Buy
- Analyst Count
- ARVN 22
- CGEM 7
- Target Price
- ARVN $20.21
- CGEM $26.57
- AVG Volume (30 Days)
- ARVN 1.8M
- CGEM 361.7K
- Earning Date
- ARVN 10-29-2025
- CGEM 08-07-2025
- Dividend Yield
- ARVN N/A
- CGEM N/A
- EPS Growth
- ARVN N/A
- CGEM N/A
- EPS
- ARVN N/A
- CGEM N/A
- Revenue
- ARVN $372,800,000.00
- CGEM N/A
- Revenue This Year
- ARVN $4.87
- CGEM N/A
- Revenue Next Year
- ARVN N/A
- CGEM N/A
- P/E Ratio
- ARVN N/A
- CGEM N/A
- Revenue Growth
- ARVN 299.57
- CGEM N/A
- 52 Week Low
- ARVN $5.90
- CGEM $6.85
- 52 Week High
- ARVN $29.61
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- ARVN 60.55
- CGEM 50.23
- Support Level
- ARVN $7.62
- CGEM $7.31
- Resistance Level
- ARVN $8.22
- CGEM $7.82
- Average True Range (ATR)
- ARVN 0.31
- CGEM 0.39
- MACD
- ARVN 0.10
- CGEM 0.01
- Stochastic Oscillator
- ARVN 76.98
- CGEM 40.59
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.